MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
3. Government_Funders & Regulators
*Government: International
Europe
*Europe: Regions
*Western Europe
Ireland
*Industry: Ireland
Merck & Co., Inc. (NYSE:MRK)
Organization & Developments: Merck & Co, Inc.
Parents
Merck & Co., Inc. (NYSE:MRK)
Children
*California Institute for Biomedical Research, or CalIBR
*Human papillomavirus vaccine
*Keytruda (pembrolizumab)
*Medical Information and Innovation or M2i2
*Merck Foundation
*Merck Human Health Division
*Merck: Brands
*MSD
*StayWell, a MediMedia company
*The Merck Group - History - Founded 1668
2005: 1999 = 10 alliances vs 2005 =47 (Reviewed 5, 000 potential partnerships)
2006: 52 compounds in human testing (2006) up from 16 in 2002
2015: Lilly, Merck join Valeant in DOJ spotlight with new inquiries on pricing
2016: Biotech Forum Daily Digest: Tesaro's Huge Week! Brexit Losses Gone, Spotlight On Applied Genetics Technologies
2016: Ligand Pharma Adds Tech, Grows On Partners’ Success
2017: Can Xencor Continue To Rally? - Xencor, Inc. (NASDAQ:XNCR)
2017: Diagnosing Merck (Part 1 Of 2) - Merck & Co Inc. (NYSE:MRK)
2017: Diagnosing Merck (Part 2 Of 2) - Merck & Co Inc. (NYSE:MRK)
2017: HHS_EBOLA Vaccine
2017: Invenra, Developer of Therapeutic Antibodies, Raises $2.9M
2017: Merck, citing 'ebb and flow' in priorities, plots 1,800 sales layoffs and new chronic care focus
2017: On January 17, 2017, BioLine Rx announced that it was initiating phase 2A trials for BL-8040 in collaboration with Merck and The University of Texas MD Anderson Cancer Center
2017: SCYNEXIS: Why RBC Capital Has It As 'Outperform' With Huge Potential Upside - SCYNEXIS, Inc. (NASDAQ:SCYX)
2018: Geisinger, Merck Partner to Launch EHR-Integrated FHIR Apps
2019: Merck - Reasons To Like The Reward:Risk Ratio_seekingalpha.com
2019: Merck Reports Q2: Increasing My Fair Value Estimate_seekingalpha.com
2019: Merck's Latest $2.7-Billion Buy Of ArQule Brings About Precision Targeted And Diversified Approach To Cancer Therapy_seekingalpha.com
2020: BARDA_Backed by BARDA, Merck jumps into Covid-19: buying out a vaccine, partnering on another and adding antiviral to the mix – Endpoints News
2020: Merck and Ridgeback Bio Collaborate to Advance Development of Novel Antiviral Candidate, EIDD-2801
2020: Merck Takes 3 Major Shots at COVID-19: Themis, IAVI and Ridgeback Bio
2020: Merck taps Novocure's cancer-fighting electric fields for new Keytruda combination study
2021: Covid-19 roundup: France cancels order on Merck’s antiviral pill — report
2021: FDA authorizes new Merck Covid-19 pill despite scientists' concerns on its mechanism of action
2021: Merck Is A Great Relative Value And A Good Absolute Value_seekingalpha.com
2021: Merck says its new Covid pill reduces the risk of hospitalization, death by half for some patients_www.cnbc.com
2021: Merck sets up $240M Alydia Health buyout to beef up its future Organon women's health spinout
2021: Merck’s Antiviral Could Be Just What Covid Was Waiting For _Tiktok
2021: Merck’s Molnupiravir: When a Private-Public Partnership Bears Fruit
2021: Nektar Therapeutics Breaks Out On Combo Study With Merck's Keytruda
2021: U.S. government to buy $1 billion more worth of Merck's COVID-19 pill
2022: Merck & Co., Inc. 2022 Q3 - Results - Earnings Call Presentation_ seekingalpha.com
2022: Merck And Moderna Move Forward With Melanoma Vaccine - There's A Case For Backing Both_seekingalpha.com
2022: Merck pays Moderna $250M to continue Keytruda, cancer vaccine combo studies
2022: Merck: A Gem In A Period Of Economic And Geopolitical Uncertainties
2022: Merck: Great Medicine For The Portfolio_seekingalpha.com
2022: Merck: Resilient To Macroeconomic Headwinds, Attractively Valued_seekingalpha.com
2022: Merck: Why The Company Is Still Undervalued_ seekingalpha.com
2022: Moderna, Merck & Co. mRNA cancer vaccine slashes melanoma recurrence in Keytruda combo trial
2023: Merck Is Poised To Outperform In 2023_seekingalpha.com
2023: Merck Q1 Earnings: Delivering Strong Results_ seekingalpha.com
2023: Merck, Ginkgo Bioworks strike deal worth up to $490M to 'optimize' biologics manufacturing
2023: Merck: Getting Less Attractive_seekingalpha.com
2023: Merck: One Of The Best - Unveiling The Trifecta Of Safety, Dividends, And Growth_ seekingalpha.com
2023: Merck: Smart Value For Potentially Strong Total Returns_ seekingalpha.com
2023: Merck: Smart Value For Potentially Strong Total Returns_ seekingalpha.com
2024: A decade of cancer immunotherapy: Keytruda, Opdivo and the drugs that changed oncology
2024: Exclusive: US FDA finds widely used asthma drug impacts the brain
2024: Merck & Co. signs $220M macrocyclic peptide deal after hailing ‘next wave of drug discovery’
2024: Merck & Co., Inc. (MRK) JPMorgan 42nd Annual Healthcare Conference (Slides)_seekingalpha.com
2024: Merck & Co., Inc. 2023 Q4 - Results - Earnings Call Presentation
2024: Merck Enters into Exclusive Global License for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody from LaNova Medicines Ltd.
2024: Merck Has Become Very Cheap Again
2024: Merck Inks $1B Synthetic Biology Deal with Pearl
2024: Merck Q3 Earnings Review: Solid Financials May Be Undermined By New Keytruda Threat
2024: Merck, facing threat to Keytruda, buys into new kind of cancer immunotherapy
2024: Merck: A High-Conviction Investment For Long-Term Growth
2024: Merck: A Low-Hanging Fruit To Pick
2024: Merck: Among The Best Health Care GARP Plays Today
2024: Merck: Big Pharma Looks Stronger Than Ever Ahead Of 2023 Earnings
2024: Merck: Buy This Bargain Before It's Gone
2024: Merck: Keytruda's Sales Projections Outweigh Competitive And Patent Risks
2024: Merck: Seriously Undervalued At Peak Pessimism (Rating Upgrade)
2024: Merck: Seriously Undervalued At Peak Pessimism (Rating Upgrade)_ seekingalpha.com
2024: Merck: Set To Keep Soaring Post Q4 Release
2024: Merck: We Were Wrong, But The Exuberance Is Overly Done Here (Rating Upgrade)_ seekingalpha.com
2024: Merck's Future Brightens With Winrevair's Blockbuster Potential
2024: Merck's Soaring Stock: Examining The Euphoria Amidst Potential Pitfalls_ seekingalpha.com
2024: Merck’s Investigational Zilovertamab Vedotin in Combination With R-CHP Demonstrates Complete Response Rate of 100% at 1.75 mg/kg Dose in Phase 2 Trial of Previously Untreated Patients With Diffuse Large B-Cell Lymphoma
2024: Under-the-skin Keytruda comparable to infused version in Phase 3 study, Merck says
2025: #1. Keytruda (pembrolizumab) Merck & Co. 2024 Sales: $29.482 billion 2023 Sales: $25.011 billion % Change: +17.9%
2025: Big Pharma, Bigger Bargain: Why Merck Stock Is Too Cheap To Ignore (Upgrade)
2025: Merck & Co.: A Pharma Titan At A Discount
2025: Merck dives into regulatory talks after oral PCSK9 delivers 3rd phase 3 win
2025: Merck launches $22 million collaborative to improve cardiac care
2025: Merck outlines $3B reinvestment initiative and expects 1%–2% revenue growth for 2025 while advancing new product launches
2025: Merck plans $3B annual cost cuts as Keytruda faces patent cliff
2025: Merck Proves Why It's Still A Top Pharma Pick
2025: Merck Stock Is Almost A Classical Benjamin Graham Investment
2025: Merck, Eisai combo meets key goal in advanced kidney cancer trial (MRK:NYSE) | Seeking Alpha
2025: Merck: 3x Pipeline And Undervaluation Make It A Buy_seekingalpha.com
2025: Merck: Cheap Stock, But Still Relying Heavily On Keytruda (Rating Upgrade)
2025: Merck: Don't Fight The Tape, How Low Can It Go?
2025: Merck: Don't Let Today's Bargain Opportunity Pass You By
2025: New Pill From Merck Could Slash Cholesterol Levels, Trials Show
2026: Breakthrough vaccine for the deadliest skin cancer cut risk by almost half
2026: Cancer treatment could face landmark moment with promising vaccine
Merck Digital Sciences Studio
Merck's experimental pill lowered bad cholesterol as much as shots
New mRNA Vaccine Reduces Risk of Melanoma Recurrence by Over 40 Percent
Jumps
*Key People: Merck
Finance & Acquisitions: Merck & Co.